Concepedia

Author

Esther G.M. De Waal

St. Antonius Ziekenhuis

Also Known As

E. G. M. Waal, E. G. M. de Waal, Esther G. M. de Waal, Esther G.M. De Waal, Esther G.M. de Waal, I.M. Schrover

23

Publications

290

Citations

10

H-Index

9

Concepts

All Affiliations

St. Antonius ZiekenhuisMedisch Centrum LeeuwardenUniversity Medical Center GroningenErasmus MC Cancer InstituteAlbert Schweitzer Ziekenhuis
EG

About

Esther G.M. De Waal is an author at St. Antonius Ziekenhuis specializing in radiation oncology, hematology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

20

2

Medicine

1

1

20

3

Pharmacology

1

1

20

4

Clinical Trials

1

1

20

5

Hematology

1

1

20

Esther G.M. De Waal

×

7

Publications

208

Citations

7

H-Index

YearCitations

Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands

Esther G.M. De Waal, Marnix J. Leene, Nic J.G.M. Veeger,

British Journal of Haematology

2016

78

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek,

Journal of Clinical Oncology

2021

60

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

Esther G.M. De Waal, Linda de Munck, Mels Hoogendoorn,

British Journal of Haematology

2015

20

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, Kazem Nasserinejad, Ellen van der Spek,

Blood

2019

15

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

K. Groen, Claudia A.M. Stege, Kazem Nasserinejad,

EClinicalMedicine

2023

13

18F-FDG PET Increases Visibility of Bone Lesions in Relapsed Multiple Myeloma

Esther G.M. De Waal, Riemer H. J. A. Slart, Marnix J. Leene,

Clinical Nuclear Medicine

2014

12

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes

K. Groen, Febe Smits, Kazem Nasserinejad,

HemaSphere

2024

10

Page 1